Kryger Capital’s Senti Biosciences Holdings SNTI Stock Holding History

Kryger Capital’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-46,690	Closed	-$4.61M	–	215
2022 Q1	$4.61M	Buy	46,690 +3,172	+7%	+$313K	0.26%	82
2021 Q4	$4.29M	Buy	+43,518	New	+$4.34M	0.24%	88

Other funds holding SNTI

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Intel Corp Santa Clara, California $470M AUM 21.74% 1-Year Est. Return

Financial Management Network Mission Viejo, California $653M AUM 17.76% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Kingfisher Capital Charlotte, North Carolina $437M AUM 41.72% 1-Year Est. Return

Kryger Capital's SNTI Position: Q2 2022 in Review

Kryger Capital sold out of Senti Biosciences Holdings (SNTI) in Q2 2022, closing a stake of 46,690 shares — an estimated $4.61M sold.

Kryger Capital first reported a position in SNTI in Q4 2021 and held it in 2 quarters. The position peaked at $4.61M in Q1 2022. 22 funds tracked by Wall St. Rank hold SNTI as of Q2 2022.

Kryger Capital reported no remaining Senti Biosciences Holdings position as of Q2 2022 after selling out during the quarter.
Kryger Capital sold 46,690 Senti Biosciences Holdings shares in Q2 2022, an estimated $4.61M.
Kryger Capital first reported a position in Senti Biosciences Holdings in Q4 2021 and held it in 2 quarters.
Kryger Capital's Senti Biosciences Holdings position peaked at $4.61M in Q1 2022.
22 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2022.

Based on Kryger Capital's 13F filing for Q2 2022, filed 15 Aug 2022.